Abstract
Cancer stem cells (CSCs) were identified in human leukemias in landmark studies of John Dick and his colleagues. Subsequently, similar cancer stem-like cells were identified in solid tumors of the breast, colon, brain and other sites. CSCs have distinct markers and are highly tumorigenic compared to other subsets. They can differentiate into all the cell phenotypes of the parental tumor. Other key features include activation of pluripotency genes (Oct4, Sox2, Nanog), self-renewal, formation of tumor spheres in low-adherence cultures, and multi-drug resistance. Clinically, drug resistance is probably the most important feature, because CSCs resist conventional cancer therapies and are likely to play a major role in cancer relapse. Based on their properties, several molecules have been targeted for therapy with drugs as follows. 1) The self-renewal pathways Wnt/β-catenin, Hedgehog and Notch. 2) The aryl hydrocarbon receptor (AHR), with tranilast and other AHR agonists. 3) Cytokines and inflammatory pathways (e.g., IL-6, IL-8, NF-κB). 4) TGF-β and epithelial- to-mesenchymal transition (EMT) pathways. 5) Homing molecules involved in metastasis; most notably CXCR4 or its ligand CXCL12. 6) Growth factors, their receptors and coreceptors (such as neuropilin-1), and signaling components (e.g., tyrosine kinases). 7) Cell-surface markers (CD44 and integrins). Several drugs have been identified by screening or other observations (salinomycin, metformin, tesmilifene, sulforaphane, curcumin, piperine and others). Some of these drugs are at preclinical or early clinical phases of development, and it remains to be seen how many will progress to clinical application. This review focuses on some promising new developments in anti-CSC drug therapy.
Keywords: Aryl hydrocarbon receptor, cancer stem cell, epithelial-to-mesenchymal transition, mammosphere, neuropilin, Oct4, transforming growth factor beta, tranilast, anti-CSC drug therapy
Current Pharmaceutical Design
Title:Cancer Stem Cells and Novel Targets for Antitumor Strategies
Volume: 18 Issue: 19
Author(s): Gerald J. Prud’homme
Affiliation:
Keywords: Aryl hydrocarbon receptor, cancer stem cell, epithelial-to-mesenchymal transition, mammosphere, neuropilin, Oct4, transforming growth factor beta, tranilast, anti-CSC drug therapy
Abstract: Cancer stem cells (CSCs) were identified in human leukemias in landmark studies of John Dick and his colleagues. Subsequently, similar cancer stem-like cells were identified in solid tumors of the breast, colon, brain and other sites. CSCs have distinct markers and are highly tumorigenic compared to other subsets. They can differentiate into all the cell phenotypes of the parental tumor. Other key features include activation of pluripotency genes (Oct4, Sox2, Nanog), self-renewal, formation of tumor spheres in low-adherence cultures, and multi-drug resistance. Clinically, drug resistance is probably the most important feature, because CSCs resist conventional cancer therapies and are likely to play a major role in cancer relapse. Based on their properties, several molecules have been targeted for therapy with drugs as follows. 1) The self-renewal pathways Wnt/β-catenin, Hedgehog and Notch. 2) The aryl hydrocarbon receptor (AHR), with tranilast and other AHR agonists. 3) Cytokines and inflammatory pathways (e.g., IL-6, IL-8, NF-κB). 4) TGF-β and epithelial- to-mesenchymal transition (EMT) pathways. 5) Homing molecules involved in metastasis; most notably CXCR4 or its ligand CXCL12. 6) Growth factors, their receptors and coreceptors (such as neuropilin-1), and signaling components (e.g., tyrosine kinases). 7) Cell-surface markers (CD44 and integrins). Several drugs have been identified by screening or other observations (salinomycin, metformin, tesmilifene, sulforaphane, curcumin, piperine and others). Some of these drugs are at preclinical or early clinical phases of development, and it remains to be seen how many will progress to clinical application. This review focuses on some promising new developments in anti-CSC drug therapy.
Export Options
About this article
Cite this article as:
J. Prud’homme Gerald, Cancer Stem Cells and Novel Targets for Antitumor Strategies, Current Pharmaceutical Design 2012; 18 (19) . https://dx.doi.org/10.2174/138161212800626120
DOI https://dx.doi.org/10.2174/138161212800626120 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Serum Proteomic Analysis of the Patients Suffering with End Stage Renal Disease and Left Ventricular Hypertrophy
Current Biomarkers (Discontinued) 3D Modelling of Three Pro-Inflammatory Molecules in Selected Fish Species
Current Pharmaceutical Design Obesity and Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Curcumin: A Boon to Colonic Diseases
Current Drug Targets Resolving Inflammation in Heart Failure: Novel Protective Lipid Mediators
Current Drug Targets Enzymes Oxidizing the Azo Dye 1-Phenylazo-2-Naphthol (Sudan I) and their Contribution to its Genotoxicity and Carcinogenicity
Current Drug Metabolism Colchicine: An Ancient Drug with Multiple Benefits
Current Pharmaceutical Design Lentiviral-Mediated Gene Therapy in Fanconi Anemia-A Mice Reveals Long-Term Engraftment and Continuous Turnover of Corrected HSCs
Current Gene Therapy Identification of Target Antigens of Antiendothelial Cell Antibodies Against Human Brain Microvascular Endothelial Cells in Healthy Subjects
Current Neurovascular Research Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Medical and Societal Impact
Current Immunology Reviews (Discontinued) Beta-Adrenergic Antagonists: Indications and Potential Immunomodulatory Side Effects in the Critically Ill
Current Medicinal Chemistry Anti-Inflammatory Drugs and Herbs with Special Emphasis on Herbal Medicines for Countering Inflammatory Diseases and Disorders - A Review
Recent Patents on Inflammation & Allergy Drug Discovery The Psychopharmacology of Appetite: Targets for Potential Anti-Obesity Agents
Current Medicinal Chemistry - Central Nervous System Agents Review of Novel Aspects of the Regulation of Ghrelin Secretion
Current Drug Metabolism Dengue: Recent Advances in Biology and Current Status of Translational Research
Current Molecular Medicine Imaging Epigenetics in Alzheimer’s Disease
Current Pharmaceutical Design Rheumatic Manifestations Associated with Inflammatory Bowel Diseases
Current Rheumatology Reviews Mechanisms of Action of Non-Steroidal Anti-Inflammatory Drugs for the Prevention of Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Alzheimers Disease and Oxidative Stress: The Old Problem Remains Unsolved
Current Medicinal Chemistry - Central Nervous System Agents 4-Thiophenoxy-N-(3,4,5-Trialkoxyphenyl)Pyrimidine-2-Amines as Potent and Selective Inhibitors of the T-Cell Tyrosine Kinase p56lck
Current Medicinal Chemistry